Esteve Pharmaceuticals, S.A.
https://www.esteve.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Esteve Pharmaceuticals, S.A.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Keeping Up The Pressure In Pulmonary Arterial Hypertension
Merck & Co leads a market expected to exceed $10bn by 2028, but others are aiming to muscle in.
Marching On: Eight Novel Agents Among March Goal Dates For US FDA
Crowded calendar could bring to an end the slow start for novel approvals in 2024, as decisions come due for Lilly’s donanemab, Merck’s sotatercept, Regeneron’s odronextamab and more.
MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Esteve Teijin Healthcare (ETH)
- Laboratorios del Dr. Esteve, S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice